Exclusivity Period Allowed By OTC Monograph Reform Likely Up To Conference Committee
This article was originally published in The Rose Sheet
Next step for OTC monograph reform legislation is Senate consideration; market exclusivity periods are likely focus of House/Senate conference. Separate bill to allow consumers to use health savings accounts to buy OTC drugs without a doctor's prescription clears House Ways and Means panel.
You may also be interested in...
Top US FDA Drug Policy Leader Leaving For White House Detail
Grail Sipes, CDER deputy center director for regulatory policy, will move to the Executive Office of the President next month.
At US FDA, Adding ‘Effective’ Staff For Overhauled OTC Monograph Program ‘Really Takes Time’
CDER’s Office of Nonprescription Drugs is “hitting the deck running’” hiring and training staff following passage of OTC monograph reform with user fees to support adding staff and a reshuffling earlier in 2020, says Peter Stein, Office of New Drugs director.
US OTC Monograph Reform's Early Results Could Be Label Orders From FDA, Wait And See For Industry
With much of FDA's work currently focused on the COVID-19 pandemic, the agency has limited resources available to implement monograph changes authorized by recent legislation. Drug firms awaited a monograph overhaul with expectations for success where they previously failed, but they need FDA's guidance to succeed.